ArmaGen Technologies, a US-based life sciences company known as Neurogene Technologies until 2004, has raised $17m in its series A round from four corporations.

Boehringer Ingelheim Venture Fund, the corporate venturing unit of the eponymous Germany-based healthcare company, led the A round syndicate, which also included drug peers Shire and Takeda’s venturing units, and Japan-based financial conglomerate Mitsui’s Global Investment division.

William Pardridge, founder and chief scientific officer of ArmaGen and professor of medicine
 and director of the Blood Brain…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?